# Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids

> **NCT01601821** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 245 (actual)

## Conditions studied

- Inflammation

## Interventions

- **DRUG:** CsA+Rapamune+CS
- **DRUG:** CsA+MMF+CS

## Key facts

- **NCT ID:** NCT01601821
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2018-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01601821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01601821, "Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01601821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*